The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells transplantation for hematological diseases.
- Author:
Hui-sheng AI
1
;
Chang-lin YU
;
Dan-hong WANG
;
Mei GUO
;
Jian-hui QIAO
;
Bao-fu SHI
;
Wan-jun SUN
;
Shi ZHANG
;
Qi-yun SUN
;
Bo YAO
Author Information
- Publication Type:Journal Article
- MeSH: Acute Disease; Adolescent; Adult; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; etiology; Hematologic Diseases; mortality; therapy; Humans; Leukocyte Count; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; adverse effects; Platelet Count; Survival Analysis; Survival Rate; Transplantation Chimera; blood; Transplantation Conditioning; methods; Transplantation, Homologous; Treatment Outcome
- From: Chinese Journal of Hematology 2003;24(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the significance of nonmyeloablative allogeneic peripheral blood hematopoietic stem cell transplantation in the treatment of hematological diseases.
METHODSA nonmyeloablative conditioning regimen consisted of CD(3) monoclonal antibody, cyclosporine A, cyclophosphamide and cytarabine was used for allogeneic stem cell transplantation in 33 patients with hematological diseases. Of them, 11 were acute leukemia (AL) in first complete remission (CR(1)), 4 AL-CR(2) approximately 3, 3 refractory AL, 4 severe aplastic anemia (SAA), 7 chronic myeloid leukemia (CML), 2 myelodysplastic syndrome, 1 each of chronic lymphocytic leukemia (CLL) and myelofibrosis.
RESULTSAll 33 patients passed the hematopoietic suppression stage smoothly and achieved engraftment of the donor cells. There were 24 cases of full donor chimerism (13 cases converted from mixed chimerism), 4 mixed chimerism (MC) and 5 developed graft rejection. Of the 33 cases, 7 (21.2%) developed acute GVHD and chronic GVHD, 25 (75.8%) still live and 8 (24.2%) died.
CONCLUSIONSNonmyeloablative allogeneic peripheral blood stem cells transplantation is a safe, less toxic and curative approach for patients with hematological disease.
